Open Access
| Issue |
BIO Web Conf.
Volume 240, 2026
The 2026 International Conference on Biomedicine, Neuroscience and Biostatistics (ICBNB 2026)
|
|
|---|---|---|
| Article Number | 01026 | |
| Number of page(s) | 8 | |
| Section | Biomedicine, Neuroscience and Biostatistics | |
| DOI | https://doi.org/10.1051/bioconf/202624001026 | |
| Published online | 24 June 2026 | |
- J. Ferlay, M. Ervik, F. Lam, Global cancer observatory: Cancer today. Lyon: International Agency for Research on Cancer. Cancer Tomorrow. 71, 3 (2024) [Google Scholar]
- H. Sung, J. Ferlay, R.L. Siegel, Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clin. 74, 175 (2024) [Google Scholar]
- C. Gridelli, Chemotherapy for advanced non-small-cell lung cancer. N. Engl. J. Med. 373, 1617 (2015) [Google Scholar]
- D.S. Ettinger, NCCN Guidelines Insights: Non-Small Cell Lung Cancer. J. Natl. Compr. Cancer Netw. 14, 255 (2016) [Google Scholar]
- E.B. Garon, Five-year overall survival with pembrolizumab in advanced NSCLC. J. Clin. Oncol. 37, 2404, (2019) [Google Scholar]
- M.A. Postow, Five-year follow-up of nivolumab in advanced NSCLC. N. Engl. J. Med. 379, 1550, (2018) [Google Scholar]
- Y. Zhang, J. Li, H. Wang, Reprogramming the immune microenvironment in lung cancer. Front. Immunol. 16, 1684889 (2025). https://doi.org/10.3389/fimmu.2025.1684889. [Google Scholar]
- M.F. Sanmamed, I. Eguren-Santamaria, K.A. Schalper, Overview of lung cancer immunotherapy. Cancer J. 26, 473 (2020) [Google Scholar]
- P. Fan, Z. Qi, Z. Liu, High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers. Cell Death Dis. 51, 628 (2025) [Google Scholar]
- A. Lahiri, A. Maji, P.D. Potdar, Lung cancer immunotherapy: progress, pitfalls, and promises. Mol. Cancer. 22, 40 (2023) [Google Scholar]
- A. Mariniello, M. Borgeaud, M. Weiner, Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: From bedside to bench and back. BioDrugs. 39, 215 (2025) [Google Scholar]
- J.U. Lim, E. Lee, S.Y. Lee, Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer. Transl. Lung Cancer Res. 12, 857 (2023) [Google Scholar]
- J. Kim, S. Park, H. Lee, Immunological biomarkers predicting response to anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. Front. Immunol. 16, 1597686 (2025) [Google Scholar]
- M. Li, H. Zhang, Y.Wang, The tumor microenvironment in lung cancer: Heterogeneity, therapeutic resistance and emerging treatment strategies. Int J Oncol. 68, 5824 (2025) [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.